Analysis of Whole Blood Tacrolimus Concentrations in Liver Transplant Patients Exhibiting Impaired Liver Function

1999 ◽  
Vol 21 (6) ◽  
pp. 585 ◽  
Author(s):  
Gordon D. MacFarlane ◽  
Leslie M. Shaw ◽  
Raman Venkataramanan ◽  
Richard Mullins ◽  
Daniel G. Scheller ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Transplant ◽  
Whole Blood ◽  
Impaired Liver Function ◽  
Transplant Patients ◽  
Impaired Liver

scholarly journals Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients

1996 ◽  
Vol 42 (9) ◽  
pp. 1426-1432 ◽  
Author(s):  
A K Gonschior ◽  
U Christians ◽  
M Winkler ◽  
A Linck ◽  
J Baumann ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Transplant ◽  
Kidney Transplant ◽  
Parent Drug ◽  
Normal Liver ◽  
Liver Graft ◽  
Tacrolimus Concentration ◽  
Impaired Liver Function ◽  
Transplant Patients ◽  
Kidney Transplant Patients

Abstract The metabolite patterns of tacrolimus in blood were evaluated in 41 kidney and liver graft recipients. Trough concentrations of tacrolimus and its metabolites were measured by HPLC-mass spectrometry and microparticle enzyme immunoassay in parallel. A statistically significant correlation between results of both assays was observed for kidney and liver transplant patients (r = 0.77, P <0.001 and r = 0.71, P <0.001, respectively). The main metabolites in blood were demethyl, demethylhydroxy, didemethyl, didemethylhydroxy, and hydroxy tacrolimus. These metabolites added up to 42% (range 0-145%) of the tacrolimus concentration in liver transplant patients and to 44.8% (range 16-152%) in kidney transplant patients. During episodes of impaired liver function, concentrations of tacrolimus and its metabolites were increased compared with normal liver function, indicating accumulation of metabolites, in particular second-generation metabolites such as didemethyl and didemethylhydroxy tacrolimus. Stepwise regression analysis including tacrolimus, its metabolites, and liver function parameters suggested a model including serum activities of gamma-glutamyltransferase, alkaline phosphatase, and alanine aminotransferase as predictors for increased concentrations of demethyl tacrolimus, didemethyl tacrolimus, and the parent drug.

Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

1985 ◽  
Vol 54 (03) ◽  
pp. 617-618 ◽  
Author(s):  
J C Kirchheimer ◽  
K Huber ◽  
P Polterauer ◽  
B R Binder
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Liver Function ◽  
Matched Control ◽  
Malignant Growth ◽  
Control Groups ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Specific Medication ◽  
History Of

SummaryPlasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.

scholarly journals A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD

2015 ◽  
pp. 93 ◽  
Author(s):  
Rajshekhar Chakraborty ◽  
Shiva Kumar Reddy Mukkamalla ◽  
Garfield Gutzmore ◽  
Hon Cheung Chan
Keyword(s):  
Liver Function ◽  
Impaired Liver Function ◽  
Impaired Liver

Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function

2002 ◽  
Vol 13 (8) ◽  
pp. 847-849 ◽  
Author(s):  
Sebastian Bauer ◽  
Volker Hagen ◽  
Hermann J Pielken ◽  
Peter Bojko ◽  
Siegfried Seeber ◽  
...  
Keyword(s):  
Liver Function ◽  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Impaired Liver Function ◽  
Stromal Tumors ◽  
Impaired Liver

Abstract 15268: Development of a Reliable Means of Assessment of Liver Function After the Fontan Operation: Dual Cholate Clearance Assay

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Yuli Y Kim ◽  
Greg Everson ◽  
Steve Helmke ◽  
Jessica Carducci ◽  
Andrew C Glatz ◽  
...  
Keyword(s):  
Liver Function ◽  
Fontan Operation ◽  
Hepatic Clearance ◽  
Severity Index ◽  
Hepatic Function ◽  
Shunt Fraction ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Fontan Patients ◽  
Normal Controls

Introduction: Currently there is no biomarker or test to accurately measure liver function in Fontan-associated liver disease. The dual cholate test (HepQuant SHUNT) is a noninvasive, flow-dependent assay measuring hepatic clearance of a bile acid, cholate, and may serve as a useful measure of liver function in the Fontan. We aim to measure cholate clearance in a cohort of Fontan patients and compare to normal controls. Methods: Single center, prospective pilot study of Fontan patients ≥ 18 years. Hepatic clearance of orally administered d4-cholate and intravenously administered 13C-cholate were measured in peripheral venous samples after 5, 20, 45, 60, and 90 minutes. Portal hepatic filtration rate (HFR), systemic HFR, shunt fraction (systemic HFR/portal HFR), and disease severity index (DSI) were calculated. Decline in HFRs and increase in shunt fraction or DSI is indicative of impaired liver function. Two-sided t-tests were used to compare values between Fontans and controls. Results: Twelve Fontan patients were enrolled (33% female, median age 29.9 [range 23.6 - 41.0] years). Median total bilirubin was 0.8 (range 0.3-2.1) mg/dL, AST 30.5 (range 16-55) U/L, ALT 32 (range 11-53) U/L, alkaline phosphatase 87 (range 42-191) U/L and platelets 177 (range 130-428) 10 3 /μL. Mean cardiac index was 3.0 ± 0.5 L/min/m 2 . Cholate clearance was lower in Fontans compared to controls (Figure). Mean portal HFR (mL/min/kg) in Fontans was lower than controls (15.1 ± 10.9 vs 29.1 ± 9.0; p<0.001) as well as systemic HFR (3.7 ± 1.3 vs 6.5 ± 1.5; p<0.001) whereas shunt fraction (%) was not (29.2 ± 11.4 vs 24.1 ± 7.5; p=NS). DSI was higher in Fontans compared to controls (19.4 ± 6.1 vs 9.2 ± 3.4; p<0.001). Conclusions: Fontan patients demonstrate reduced hepatic function compared to normal controls but there is considerable variability. Future studies using the dual cholate test will examine the relationship between liver and cardiac function, as well as risk of adverse clinical outcome, in the Fontan.

Sign in / Sign up

Export Citation Format

Share Document